Hematopoiesis News Volume 6.30 | Aug 4 2015

C/EBPα Activates Pre-Existing and De Novo Macrophage Enhancers during Induced Pre-B Cell Transdifferentiation and Myelopoiesis
Scientists showed that during pre-B-cell-to-macrophage transdifferentiation, C/EBPα binds to two types of myeloid enhancers in B cells: pre-existing enhancers that are bound by PU.1, providing a platform for incoming C/EBPα; and de novo enhancers that are targeted by C/EBPα, acting as a pioneer factor for subsequent binding by PU.1. [Stem Cell Reports] Full Article | Graphical Abstract | Press Release

The Fanconi Anemia Pathway Is Required for Efficient Repair of Stress-Induced DNA Damage in Hematopoietic Stem Cells
Previously, the authors demonstrated such stress-associated DNA damage was sufficient to completely deplete hematopoietic stem cells and promote severe aplastic anemia (SAA) in the Fanconi anemia (FA) knockout mouse model, which has compromised replication-associated DNA repair. They extended this previous work to show that FA mice do not spontaneously develop a hematopoietic phenotype consistent with SAA, even at extreme old age. [Cell Cycle] Abstract

Impaired Hematopoiesis and Disrupted Monocyte/Macrophage Homeostasis in Mucopolysaccharidosis Type I Mice
Investigators evaluated alterations in hematopoiesis and its implications on the production of mature progeny in a mucopolysaccharidosis type I murine model. Despite the significant increase in hematopoietic stem cells, a reduction in common myeloid progenitors and granulocyte-macrophage progenitor cells was observed in Idua^-/- mice bone marrow. [J Cell Physiol] Abstract

Non-Hematopoietic and Hematopoietic SIRPα Signaling Differently Regulates Murine B Cell Maturation in Bone Marrow and Spleen
Scientists provide evidence that signal regulatory protein alpha (SIRPα), an Ig-superfamily ITIM-receptor expressed by myeloid but not by lymphoid cells, is involved in regulating B cell maturation. [PLoS One] Full Article

CLINICAL RESEARCH

Outcome of Children with Acute Myeloid Leukemia (AML) Experiencing Primary Induction Failure in the AIEOP AML 2002/01 Clinical Trial
Investigators report the clinical and biological data, and final outcome of 48 pediatric patients with primary-resistant AML enrolled in the Associazione Italiana di Ematologia e Oncologia Pediatrica AML 2002/01 clinical trial. [Br J Haematol] Abstract

Allogeneic Hematopoietic Stem Cell Transplantation Could Improve Survival of Cytogenetically Normal Adult Acute Myeloid Leukemia Patients with DNMT3A Mutations
Researchers retrospectively analyzed the prognostic impact of DNMT3A mutations and explored the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in 308 cytogenetically normal acute myeloid leukemia patients who received consolidation of intensive chemotherapy or allo-HSCT. [Am J Hematol] Abstract

Extramedullary Hematopoiesis Is Associated with Lower Cardiac Iron Loading in Chronically Transfused Thalassemia Patients
Investigators evaluated in a large cohort of chronically transfused patients whether the presence of extramedullary hematopoiesis accounts for the typical patterns of cardiac iron distribution and/or cardiac function parameters. [Am J Hematol] Abstract

Anti-Thymocyte Globulin Could Improve the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Highly Aggressive T-Cell Tumors
Researchers used the anti-thymocyte globulin as the part of the conditioning regimen and evaluated the long-term anti-leukemia effect, the safety and complication in the patients with highly aggressive T-cell lymphomas. [Blood Cancer J] Full Article

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Juno Announces FDA Clearance of Investigational New Drug Application for JCAR015 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
Juno Therapeutics, Inc. announced the U.S. Food and Drug Administration (FDA) cleared the company’s investigational new drug application for JCAR015 for treatment of adult patients with relapsed/refractory acute lymphoblastic leukemia. [Juno Therapeutics, Inc.] Press Release

Stem Cell Transplant Program Earns International Accreditation
The Stem Cell Transplant Program at the University of Virginia Cancer Center has received international accreditation for its use of stem cells and bone marrow to treat patients with blood cancers. [University of Virginia Cancer Center] Press Release

From our sponsor: Learn about detecting cancer stem cells with ALDEFLUOR™. Watch the webinar.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoiesis community.

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Hematopoietic Regeneration and Myeloid Malignancies (Weill-Cornell Medical College)

Postdoctoral Position – Hematopoietic Stem and Progenitor Cell Assays (Weill Cornell Medical School)

Research Associate – Cell Biology (Editas Medicine)

Postdoctoral Position – Splicing in Hematopoiesis (Northwestern University)

Clinical Research Coordinator – Chronic Lymphocytic Leukemia (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Hematopoietic Stem Cell Transplantation (St. Jude Children’s Research Hospital)

Postdoctoral Position – Hematopoietic Stem Cell and Hematologic Malignancy (University of Kentucky College of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.